Characteristics and Developments in Mesenchymal Stem Cell Therapy for COVID-19: An Update

Table 1

Clinical trials investigated the use of MSCs for COVID-19 treatment marked “completed” on clinicaltrials.gov.

Trial ID no.	Status	Responsible country	Study title	Interventions
NCT04288102	Completed	China	Treatment with human umbilical cord-derived mesenchymal stem cells for severe corona virus disease 2019 (COVID-19)	UC-MSCs
NCT04355728	Completed	United States	Use of UC-MSCs for COVID-19 patients	UC-MSCs
NCT04492501	Completed	Pakistan	Investigational treatments for COVID-19 in tertiary care hospital of Pakistan	MSCs
NCT04522986	Completed	Japan	An exploratory study of ADR-001 in patients with severe pneumonia caused by SARS-CoV-2 infection (COVID-19)	AD-MSCs
NCT04535856	Completed	Indonesia	Therapeutic study to evaluate the safety and efficacy of DW-MSC in COVID-19 patients (DW-MSC)	MSCs
NCT04573270	Completed	United States	Mesenchymal stem cells for the treatment of COVID-19	UC-MSCs
NCT04713878	Completed	Turkey	Mesenchymal stem cells therapy in patients with COVID-19 pneumonia	MSCs

UC-MSCs: human umbilical cord mesenchymal stem cells; AD-MSCs: adipose-derived mesenchymal stem cells.